Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Cancer Immunol Res. 2014 May 20;2(8):812–821. doi: 10.1158/2326-6066.CIR-14-0013

Table 2.

Univariate analysis of relationship between m-MDSC and overall survival at pre-treatment baseline and week 6 after ipilimumab.

Ipilimumab Treated
Pre-treatment Week 6
n HR (95% CI) p-value n HR (95% CI) p-value
MDSC < 14.9% 68 0.35 (0.18 – 0.70) 0.002 64 0.38 (0.19 – 0.75) 0.004
ALC ≥1000 cells/µl 68 0.73 (0.41 – 1.33) 0.303 64 0.22 (0.11 – 0.45) < 0.001
LDH < 250 68 0.33 (0.18 – 0.59) <0.001 65 0.37 (0.20 – 0.68) 0.001
Monocytes < 300 cells/µl 68 0.70 (0.25 – 1.95) 0.495 64 1.77 (0.69 – 4.51) 0.233